Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 6/20 | 0.49 |
| ▸ | ELOVL1 | Q9BW60 | 14/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4715013 | 1.00 | NPY5R (0.49) | NPY5RELOVL1DRD3 | |
| SCHEMBL4714629 | 0.86 | NPY5R (0.66) | NPY5RELOVL1DRD3 | |
| SCHEMBL4714625 | 0.86 | NPY5R (0.66) | NPY5RELOVL1DRD3 | |
| SCHEMBL4718162 | 0.84 | NPY5R (0.54) | NPY5RELOVL1DRD3 | |
| SCHEMBL4718159 | 0.84 | NPY5R (0.54) | NPY5RELOVL1DRD3 | |
| SCHEMBL4713339 | 0.82 | NPY5R (0.53) | NPY5RELOVL1DRD3 | |
| SCHEMBL4713343 | 0.82 | NPY5R (0.53) | NPY5RELOVL1DRD3 | |
| SCHEMBL4713860 | 0.79 | NPY5R (0.75) | NPY5RELOVL1DRD3 | |
| SCHEMBL4713857 | 0.79 | NPY5R (0.75) | NPY5RELOVL1DRD3 | |
| SCHEMBL4718222 | 0.79 | NPY5R (0.53) | NPY5RELOVL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483266-B1 | SPIRO COMPOUNDS WITH NPY ANTAGONISTIC ACTIVITY | BANYU PHARMA CO LTD (JP) | 2008-02-27 | — | — | EP | claimed |
| US-20050032820-A1 | Novel spiro compounds | MSD K.K. (JP) | 2005-02-10 | — | — | US | claimed |
| EP-1483266-B1 | SPIRO COMPOUNDS WITH NPY ANTAGONISTIC ACTIVITY | BANYU PHARMA CO LTD (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-7304072-B2 | E.g.,cis-N-(4-benzoylphenyl)-4-hydroxy-3'-oxospiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-carboxamide; useful as neuropeptide Y receptor antagonists and as agents for therapy of cardiovascular disorders, central nervous system disorders, metabolic diseases, respiratory and urogenital disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-12-04 | — | — | US | disclosed |
| US-20050032820-A1 | Novel spiro compounds | MSD K.K. (JP) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032820-A1 | Novel spiro compounds | NR3C2, GPR119, NPY2R | NPY5R 62/4885ELOVL1 686/4885DRD3 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.